Table 2 Summary of baseline characteristics and medications in the non-randomised feasibility study
Age | 56.7Â years (13.7) Mean (SD) | ||
Gender | Male (67%) | ||
Duration diabetes | 7.1Â years (5.3) Mean (SD) | ||
GMS Status | 69.2% | ||
HbA1c level | 83.9Â mmol/mol (30.8) Mean (SD) | ||
SBP | 140.9Â mmHg (22.71) Mean (SD) | ||
DBP | 83.4Â mmHg (20.5) Mean (SD) | ||
Total cholesterol | 4.7Â mmol/L (1.8) Mean (SD) | ||
Prevention status | Primary prevention (81%) | ||
Glycaemic medications (37 patients valid) | No medications | 8.1% (n = 3) | – |
Monotherapy (without insulin) | 32.4% (n = 12) | Metformin (n = 2) | |
Dual therapy (without insulin) | 21.6% (n = 8) | Metformin + sulphonylurea (n = 5) Metformin + DPP-4 inhibitor (n = 2) Sulphonylurea + DPP-4 inhibitor (n = 1) | |
Triple therapy (without insulin) | 8.1% (n = 3) | Metformin + sulphonylurea + DPP-4 inhibitor (n = 3) | |
Quadruple therapy (without insulin) | 2.7% (n = 1) | Metformin + sulphonylurea + DPP-4 inhibitor + SGLT2 inhibitor (n = 3) | |
Insulin ± other medication(s) | 27.0% (n = 10) |  | |
Anti-hypertensive medications (37 valid patients) | No medications | 24.3% (n = 9) |  |
Monotherapy | 35.1% (n = 13) | ACE-inhibitor* (n = 11) Beta-blocker (n = 2) | |
Dual therapy | 13.5% (n = 5) | ACE-inhibitor + diuretic (n = 2) ACE-inhibitor + CCB (n = 2) Beta-blocker + CCB (n = 1) | |
Triple therapy | 24.3% (n = 9) | ACE-inhibitor + CCB + beta-blocker (n = 4) ACE-inhibitor + diuretic + beta-blocker (n = 2) ACE-inhibitor + CCB + diuretic (n = 1) ACE-inhibitor + CCB + alpha-blocker (n = 1) CCB + beta-blocker + ‘Other’ anti-hypertensive (n = 1) | |
Quadruple therapy | 2.7% (n = 1) | ACE-inhibitor + CCB + diuretic + diuretic (n = 1) | |
Lipid-lowering medications (37 valid patients) | No medication | 27% (n = 10) |  |
Monotherapy | 70.3% (n = 26) | Statin (n = 23) Ezetamibe (n = 2) Fibrate (n = 1) | |
Dual therapy | 2.7% (n = 1) | Statin + fibrate (n = 1) | |